Showing 111-120 of 3140 results for "".
Aesthetic A-Peel: Using Peels in Practice
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/aesthetic-a-peel-using-peels-in-practice/18556/As devices continue to evolve so do more "conventional" treatments, like peels. Dr. Gilbert talks about advancements in peels and the rise of nutraceuticals.Content Marketing
https://practicaldermatology.com/topics/practice-management/content-marketing/18316/Native advertising can help overcome shortcomings in your dermatology content distribution. This Ekwa Marketing video shows you how to do this.Analyzing IL-31 and the Benefits of Blocking It
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/analyzing-il-31-and-the-benefits-of-blocking-it/48777/James Q. Del Rosso, DO, FAOCD, discusses IL-31 and its involvement with itch, impairment of skin barrier function, and increased fibrosis of the skin.Psoriasis Comorbidities
https://practicaldermatology.com/topics/psoriasis/psoriasis-comorbidities/19729/Do you assess the gums of patients with psoriasis? Joel Gelfand, MD explains why periodontal disease may be underappreciated for what it contributes to the psoriatic disease process.What’s New in Rosacea Treatments?
https://practicaldermatology.com/conferences/science-of-skin-summit-2025/tbd/39737/James Q. Del Rosso, DO, FAOCD, reviews the latest therapeutic innovations and evidence in rosacea management. This video was recorded at the Science of Skin Summit in Austin, TX.Nail Disease and JAK Inhibitor Safety
https://reachmd.com/programs/practical-dermatology/nail-disease-and-jak-inhibitor-safety/35897/Brad Glick, DO, talks about the basics of nail anatomy, physiology, disease presentation, and treatments, as well as the safety of JAK inhibitors, at Music City SCALE 2025.Risk In Your Portfolio
https://practicaldermatology.com/topics/practice-management/risk-in-your-portfolio/18588/Do you know your risk score? Physicians must understand their personal tolerance for risk as well as the level of risk in their current portfolios. If there is a mismatch, how do you rectify the disconnect. Bob Peelman, CFP, of OJM Group, explains. ABOUT THE AUTHORThe Biosimilar Revolution: A Look at the Potential Impact
https://practicaldermatology.com/issues/april-2025/the-biosimilar-revolution-a-look-at-the-potential-impact/35596/With many biosimilars expected to gain regulatory approval in coming months and years, Practical Dermatology interviewed Collin Blattner, DO, FAAD—an editorial board member and double-board–certified dermatologist who owns Clearchoice Dermatology, which has 12 locations in Oregon and Washington—abouFrom SDPA: JAKs, Black Boxes, and What It All Means
https://practicaldermatology.com/conferences/sdpa-2024/sdpa-jaks-black-boxes-and-what-it-all-means/26286/Practitioners shouldn’t fear Janus kinase (JAK) inhibitors for their patients when appropriate, according to a wide-ranging expert chat at the 2024 SDPA Annual Summer Conference in San Diego. The conversation featured Matthew Zirwas, MD, a dermatologist with DOCS Dermatology, and Amy Spizuoco, DO, FThe Time is Now: Dermatology and Climate Change
https://practicaldermatology.com/topics/practice-management/the-time-is-now-dermatology-and-climate-change/19930/How are global warming and associated changes in weather affecting the presentation of skin diseases? And what opportunities do dermatologists have to help turn the tide of global warning? Misha Rosenbach, MD reviews the science and touches on opportunities for change.